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Abstract
Objectives. To investigate real-world short-term outcomes among patients with systemic JIA starting tocilizumab or
anakinra.
Methods. This analysis included all systemic JIA patients within the UK Biologics for Children with Rheumatic Diseases
study starting tocilizumab or anakinra between 2010 and 2016. Disease activity was assessed at baseline and one year.
At one year the following outcomes were assessed: minimal disease activity, clinically inactive disease, 90% ACR
Paediatric response (ACRPedi90). Univariable logistic regression was used to identify baseline characteristics associated
with these outcomes. Multiple imputation was used to account for missing data.
Results. Seventy-six systemic JIA patients were included (54 tocilizumab; 22 anakinra). More patients starting anakinra
as their first biologic compared with tocilizumab (86% vs 63%; P= 0.04), with shorter disease duration (1 vs 2 years;
P= 0.003) and higher frequency of prior macrophage activation syndrome (37% vs 8%; P= 0.004). Overall, at one year,
42% achieved ACRPedi90, 51% minimal disease activity, and 39% clinically inactive disease, with similar responses
seen between the two drugs. Response was not associated with baseline disease characteristics. Fifteen (20%) patients
stopped biologic treatment by one year. Treatment survival was better with tocilizumab (89% at one year vs 59%
anakinra; P= 0.002), with three stopping for anakinra injection-related problems.
Conclusion. In this real-world cohort of patients with systemic JIA receiving tocilizumab or anakinra, approximately half
achieved a minimal disease state by one year. Treatment responses appeared similar between the two therapies albeit
with better persistence observed with tocilizumab.
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Rheumatology key messages
. Tocilizumab and anakinra were effective treatments for systemic JIA; half achieved minimal disease activity.
. Treatment response appeared to be similar between systemic JIA patients treated with tocilizumab and anakinra.
. More systemic JIA patients remained on tocilizumab at one year; anakinra patients reported more injection-
related problems.
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Introduction
JIA is a diagnosis of exclusion and represents arthritis that
begins before a child turns sixteen years of age and per-
sists for at least six weeks in which no other cause has
been identified. It affects 3 in 10 000 children and young
people [1]. The current international categorisation of the
condition is the ILAR classification, which includes seven
different categories [2]. While this classification was based
predominantly on clinical characteristics, systemic JIA re-
mains clinically distinct from the other ILAR categories of
JIA, with systemic involvement including fever, rash and
enlarged lymph nodes [3]. Recent genetic analysis has
shown marked variation in the loci associated with sys-
temic JIA compared with other JIA ILAR categories [4]. In
addition, it has a markedly distinct underlying mechanism
of disease, including an important role of the innate
immune system. It is driven by specific pro-inflammatory
cytokines (e.g. IL-1, IL-6) contributing to multisystem in-
flammation [5]. This knowledge has led to different treat-
ment strategies for systemic JIA compared with other JIA
ILAR categories, with a shift away from TNF inhibitors
(TNFi) in favour of IL-6 pathway inhibitors (such as tocili-
zumab) and therapies that block IL-1 (such as anakinra or
canakinumab) [68].
Patients with systemic JIA in the United Kingdom (UK)
may be prescribed a biologic DMARD after failing or being
intolerant to the conventional synthetic DMARD metho-
trexate. TNFi were previously prescribed as a first-line bio-
logic therapy in all patients with JIA [9]. The 2015 National
Health Service England treatment pathway [10] now rec-
ommends that patients with systemic JIA be prescribed
tocilizumab (an IL-6 pathway inhibitor) or anakinra (IL-1
receptor antagonist) as a first biologic therapy following
failure of methotrexate. The exception to this is children
who present with macrophage activation syndrome (MAS)
unresponsive to intravenous steroids, who should be trea-
ted with anakinra first-line.
Since 2010, there has been a shift in the UK towards the
use of tocilizumab or anakinra as a first-line biologic fol-
lowing methotrexate in children with systemic JIA [11].
Tocilizumab is licenced for use in patients with systemic
JIA following evidence of efficacy from clinical trials
[7, 1216]. Published evidence on the use of anakinra
for JIA is limited. One small randomised controlled trial
of only one month duration found evidence of benefit
compared with placebo in patients with systemic JIA [6].
In a French retrospective study of 77 systemic JIA pa-
tients starting a first biologic (predominantly anakinra), ap-
proximately half had achieved and maintained inactive
disease after a median of over two years of follow-up
[17]. The majority of observational studies on anakinra
are low in patient number [1821]. A recent study from
the German paediatric biologics register Biologika in der
Kinderrheumatologie has investigated outcomes in pa-
tients with systemic JIA treated with either tocilizumab
or an IL-1 receptor antagonist (anakinra or canakinumab).
At one year, 27% and 35% of patients achieved an ACR
paediatric 90% response (ACR Pedi 90) on tocilizumab
and an IL-1 inhibitor respectively. There was no difference
between the two drug cohorts with respect to remission or
minimal disease activity using disease activity scores [22].
This analysis aimed to describe and compare the real-
world therapeutic short-term outcomes among children
and young people with systemic JIA starting either tocili-
zumab or anakinra in order to create an evidence base to
inform clinicians about the use of these agents in clinical
practice. The objectives of this analysis were to (1) inves-
tigate and compare baseline characteristics in all children
and young people in the UK between 2010 and 2016
starting either tocilizumab or anakinra for systemic JIA,
(2) measure and compare short-term outcomes, including
treatment response, treatment survival and stop reasons
by one year of treatment between children starting
(a) tocilizumab vs anakinra, and (b) either tocilizumab or
anakinra as a first-line vs subsequent-line biologic ther-
apy, and (3) investigate associations between baseline
characteristics and outcomes at one year.
Methods
Study setting, data capture and study population
This analysis used data collected from the UK’s Biologics
for Children with Rheumatic Diseases (BCRD) study [11].
This register, established in 2010, captures data about
children and young people with JIA starting a biologic
therapy other than Enbrel (etanercept); patients starting
Enbrel are recruited to an alternative study in the UK
[23]. Patients are recruited to the study at the point of
starting a new biologic therapy but do not have to be
biologic naı¨ve. Nationally, recruitment is recommended
[10] but not mandatory. The study was approved by the
North West 7 REC Greater Manchester Central Ethics
Committee. Written informed consent was obtained from
all parents (or patients where appropriate) in accordance
with the Declaration of Helsinki. Additional ethical ap-
proval to analyse these data was not required.
At registration, the start of biologic therapy, the treating
physician or affiliated clinical research nurse completed a
detailed questionnaire on patient demographics, disease
characteristics, ILAR classification and disease activity,
and all current and past anti-rheumatic therapies, includ-
ing prior biologics, and other medications. Follow-up
questionnaires were completed at six months, one year
and then annually thereafter. Details of changes to drug
therapy, as well as current disease activity measures,
were documented. The occurrence of any adverse
events or new health diagnoses were recorded.
Patients with systemic JIA registered starting either
tocilizumab or anakinra from 1 January 2010 with baseline
and one year data returned before 31 December 2016
were included in this study. Baseline disease characteris-
tics were assessed; including the 71-joint juvenile arthritis
disease activity score (JADAS-71) [24]. Patients were
excluded if they were in minimal disease activity (MDA)
[25] at the start of biologic therapy with no systemic fea-
tures present (n= 2). For logistical reasons, patients could
be registered into the study within six months of starting
biologic therapy, although it was requested in all cases
2 https://academic.oup.com/rheumatology
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that data entered into the study database was that reflect-
ing the start of therapy and not current measures at the
point of registration. As it was felt that these cases with
very low disease activity at the start of therapy were highly
unlikely to be correct, it was assumed their data were re-
corded after the drug had been started and therefore
these cases were excluded.
Analyses
Baseline characteristics
The baseline characteristics were compared between
patients starting anakinra vs tocilizumab. Categorical
baseline characteristics were compared used Pearson’s
chi-squared test, and continuous variables were com-
pared between groups using nonparametric K-sample
test on the equality of medians. Baseline characteristics
were also compared between patients starting either drug
as a first-line biologic vs patients who had prior biologic
exposure.
Primary outcomes
Three primary outcome measures were investigated at
one year after start of biologic; proportion achieving
MDA [25], proportion achieving clinically inactive disease
(CID) [26], and proportion achieving ACR Pedi 90 re-
sponse [27]. Both the MDA and CID criteria assess dis-
ease activity at a single time point. Patients with systemic
JIA were defined as achieving MDA if the physician global
assessment of disease activity (PGA) was no >3.4 cm, the
patient (or parent) global evaluation of well-being (PGE)
was no >2.1 cm, with a maximum of one active joint
[25]. Patients were defined as achieving CID if they had
no active joints, no systemic features, no active uveitis,
PGA of zero, and a normal ESR defined in this study as
20 mg/mm or less [26]. The ACR paediatric response cri-
terion assesses change in disease activity over time and
can be assessed with differing percentages of achieve-
ment. A patient was defined as achieving an ACR Pedi
90 if three of the six JIA core outcome variables (active
joint count, limited joint count, PGA, PGE, childhood HAQ
(CHAQ) for functional ability, and ESR) improved by at
least 90%, with a maximum of one variable worsening
by >30% [27]. Patients with a baseline core outcome vari-
able of zero who worsen over time were classified to
worsen that variable by >30%. Patients who improved
core outcome variable down to zero over time were clas-
sified to improve that variable by 100%. Patients with a
baseline core outcome variable of zero and remained at
zero over time improved by 0% (neither improved nor
worsened). Patients who stopped biologic therapy
before one year were classified as failing to achieve
these outcomes, unless the stop reason was remission,
in which case they were classified as achieving all
outcomes.
Primary outcomes were compared between patients
starting tocilizumab vs anakinra, and also between pa-
tients starting anakinra or tocilizumab as a first-line bio-
logic vs patients starting as a subsequent biologic
therapy. Statistical significance between cohorts was
assessed using logistic regression. In addition, the logistic
regression was adjusted using a propensity score to com-
pare outcomes in patients treated with tocilizumab vs ana-
kinra. The propensity score included: whether the patient
was starting it as a first-biologic, gender, age, disease
duration, concomitant methotrexate use, concomitant
steroid use, active joint count, limited joint count, PGA,
PGE, CHAQ, ESR and JADAS-71.
Secondary outcomes
Secondary effectiveness outcomes studied included the
change in active joint count, limited joint count, PGA,
PGE, CHAQ, ESR and JADAS-71, using regression
models adjusted for baseline values. A drug survival ana-
lysis was performed using a Kaplan-Meier curve to pre-
sent the proportion of patients who stopped biologic
therapy by one year. The stop reasons of therapy given
by the treating physician were categorised and described
for each drug cohort: inefficacy, remission, adverse event.
Secondary effectiveness outcomes and drug survival
were compared between patients starting tocilizumab vs
anakinra, and between patients starting either drug as
first-line biologic vs subsequent biologic. Statistical sig-
nificance between cohorts was assessed using logistic
regression for secondary effectiveness outcomes and a
log-rank test for equality of survivor functions for the
drug survival. Univariable logistic regression was used to
assess the associations of baseline characteristics with
the primary outcomes at one year, including patient char-
acteristics (age, gender), disease features (disease dur-
ation, methotrexate use, steroid use), disease activity
(including core outcome variables), and choice of treat-
ment (tocilizumab vs anakinra).
Multiple imputation (with 80 iterations based on propor-
tion of incomplete cases [28]) was used to account for
missing data. Complete variables included biologic ther-
apy (anakinra or tocilizumab), whether the patient was
starting it as a first-biologic, age at biologic start,
gender, concomitant methotrexate use, concomitant ster-
oid use, discontinuation of biologic in the first year (not for
remission). Imputed values included disease duration at
start of biologic, disease activity measures at the start of
therapy and at one year (active joint count, limited joint
count, PGA, PGE, CHAQ, ESR) and whether patient had
systemic features at one year. From the imputed values,
the outcome variables could be calculated: JADAS-71 (at
baseline and one year), change in JADAS-71 from base-
line, change in CHAQ from baseline, MDA at one year, CID
at one year, and ACR Pedi 90 response at one year. Stata
version 13 was used to perform all analyses [29].
Results
A total of 76 patients had registered fulfilling the ILAR
criteria for systemic JIA: 54 starting tocilizumab, 22 start-
ing anakinra. Table 1 shows the baseline characteristics.
In total, 57% were female, and 70% were starting a bio-
logic for the first time. The majority of patients had prior
exposure to methotrexate: 98% of tocilizumab and 86%
of anakinra (P= 0.04). Of the patients who had previously
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used a biologic therapy, 39% had used two or more. The
majority of patients with prior biologic exposure had used
a TNFi (78%), with 11 of the 20 tocilizumab patients (55%)
previously exposed to an IL-1 inhibitor, and two of the
three anakinra patients (67%) previously exposed to toci-
lizumab. Median age at start of registered biologic was
seven years old (six years for first-line biologic patients,
nine years old otherwise; P= 0.07), and median disease
duration from diagnosis to biologic treatment was one
year (one year for first-line biologic users, three years
otherwise; P< 0.001). Approximately 59% of patients
had systemic features present when starting either tocili-
zumab or anakinra and 16% had a history of MAS.
At one year, 42% of patients had achieved an ACR Pedi
90, 51% had achieved MDA, and 39% CID (Table 2).
Mean change in JADAS-71 from baseline to one year
was 14 units (P< 0.001), and mean change in CHAQ
was 0.5 units (P< 0.001). Twenty percent of the patients
reported systemic features at one year. In the univariable
logistic regression models no baseline clinical character-
istics were associated with achieving any of the three pri-
mary outcomes (Supplementary Table S1, available at
Rheumatology online), including no difference between
the two drug cohorts (tocilizumab vs anakinra), nor be-
tween patients starting biologic as first-line therapy vs pa-
tients with reporting prior biologic use. In addition, there
was no difference between tocilizumab and anakinra with
regard to achieving any of the three primary outcomes
when adjusted by the propensity score (Table 2).
Fifteen (20%) of the 76 patients stopped their pre-
scribed biologic by one year. Treatment survival was
better with tocilizumab (89%) compared with anakinra
(59%; P= 0.002) (Fig. 1). In addition, there was a trend
towards better treatment survival observed in patients
starting their first biologic (91% vs 75%), although this
was not significant (P= 0.1) (Fig. 2). One patient stopped
due to remission (anakinra), six stopped due to inefficacy
(four anakinra, two tocilizumab), seven patients stopped
due to adverse events (three tocilizumab [rash worse post
drug, neutropenia, active MAS (patient switched to ana-
kinra)], four anakinra [stomach cramps and diarrhoea, in-
jection site reaction (patient switched to etanercept),
difficulty with daily injection (n= 2; both patients switched
to tocilizumab)]), and one stopped for unknown reasons
(tocilizumab).
Discussion
This real-world, prospective, national study has demon-
strated that patients with systemic JIA starting anakinra
have similar response after one year compared with those
starting tocilizumab, with regard to disease activity, func-
tion and outcome measures. Overall, approximately half
of the patients with systemic JIA achieved a minimal dis-
ease state, and two-fifths achieved either a significant
clinical short-term response or inactive disease by one
year. There was no difference in effectiveness between
patients treated with tocilizumab or anakinra. In addition,
the proportion of patients with systemic features at one
year had reduced from baseline. In the univariable
analysis, none of the baseline characteristics were asso-
ciated with achieving any of the three primary outcomes.
One-fifth of the patients stopped biologic therapy by one
year, although this was mostly due to adverse events.
Treatment survival was better with tocilizumab at one
year compared with anakinra, with three children stopping
for anakinra injection-related problems.
It is generally reported that patients with systemic JIA
have poorer outcomes compared with non-systemic JIA
patients [3036]. However, most of these studies have
investigated cohorts of patients treated with TNFi that
do not target the pro-inflammatory cytokines typically
associated with systemic JIA [5]. One previous open
label study of 112 systemic JIA patients on tocilizumab
found 59% achieved an ACR Pedi 90 response at one
year [14]. Whereas, data from the German biologics regis-
ter BIKER found 27% of the 44 tocilizumab patients, and
35% of the 36 patients treated with an IL-1 inhibitor (either
anakinra or canakinumab) achieved an ACR Pedi 90 re-
sponse at one year [22]. A French retrospective study of
77 systemic JIA patients starting a first biologic (predom-
inantly anakinra) found approximately half achieved in-
active disease [17]. These proportions were similar to
that seen in this current prospective observational study.
In addition, only the German BIKER study compared ef-
fectiveness between IL-1 and IL-6 inhibitors and reported
no statistical difference between the two drug cohorts
[22].
Anakinra is currently (2015 onwards) recommended as
first-line therapy for patients with active MAS, as it may
help recovery [10]. However, in this study, only five of the
19 patients starting anakinra as a first-line biologic had a
reported history of MAS, although this was much higher
than patients starting tocilizumab. Further reasons why
anakinra was selected first-line instead of tocilizumab in
the remaining 11 patients was unclear. It is possible that
concerns about MAS may have influenced treatment
choice in some, but additional research is needed to ex-
plore this further.
In this study, almost all patients received methotrexate
prior to starting tocilizumab or anakinra, in keeping with
current UK guidelines [10], with a median time to first bio-
logic of one year, less for patients starting anakinra vs
tocilizumab. In part, this may relate to the fact that in
three patients (only one with a history of MAS), first-line
anakinra was used with no prior methotrexate. There is
also some evidence that suggests that there may be a
window of opportunity that very early use of anakinra is
associated with better outcomes [19, 20], although based
on the nature of this current cohort, this could not be
tested further. Among this cohort, disease duration was
not a predictor of a good clinical response.
At one year, 80% of systemic JIA patients in this study
remained on biologic therapy. This is slightly lower com-
pared with other studies of systemic JIA patients treated
with either tocilizumab [15] or anakinra [6, 18]. Treatment
survival was worse in patients receiving anakinra, with
one-third of patients who stopped anakinra reporting in-
jection-related problems. As anakinra is a daily
https://academic.oup.com/rheumatology 5
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subcutaneous injection, this has the potential to cause
both physical and mental stress to the patient and/or
their families. In contrast, all patients receiving tocilizumab
in this study received it intravenously. Although it is im-
portant to note that fortnightly intravenous injections of
tocilizumab may also be a great burden on the patients
and their families.
The BCRD study represents one of the largest national
cohorts of patients with JIA starting a non-Enbrel biologic.
Registration into the study is highly encouraged by
National Health Service England, as all patients starting
a biologic should be offered the option of enrolment [10].
Therefore, it is likely that the numbers reported in this
analysis were representative of the UK population. As is
common in observational datasets, missing data were
noted, particularly in the recording of the core outcome
variables despite proactive data follow-up and capture
across sites to minimise missing data. We used standar-
dised, multiple imputation to account for this, as in all
children we had information on at least some aspects of
disease activity at each time point. By using multiple pri-
mary outcome measures within this analysis, the aim was
to make a more generalised estimate of patient response
to treatment. The ACR paediatric response criteria were
initially created for non-systemic JIA patients to use in
clinical trials [27]. Consequently adapting the criteria to
patients with potentially very few joints affected within
an observational study is challenging. The adaptations
noted in the methods aimed to highlight that those pa-
tients improving their core outcome variables to zero
had a positive response, and patients worsening from
zero at baseline were non-responders. This remains in
line with the methods from the German BIKER register
[22]. A propensity score was used to balance any
observed differences in patients starting the two biologic
therapies. However, it is important to note that this will not
account for any unmeasured confounding between the
two therapies. Until this is replicated in greater patient
numbers, we should remain cautious of the comparable
effectiveness of tocilizumab and anakinra. While no asso-
ciations were observed between clinical features and
treatment response outcomes at one year, replicating
the results from the German BIKER register [22], statistical
significance may have been limited by power. Previous
studies looking at the TNFi etanercept (Enbrel) [31, 36]
have also failed to find a significant number of clinical
variables associated with response. However, important
short-term outcomes were able to be assessed within this
analysis and as the BCRD study continues to recruit pa-
tients, and those within the study spend longer under
follow-up, longer-term outcomes may be investigated in
the future.
In this real-world cohort of patients with systemic JIA
starting tocilizumab or anakinra, approximately half
achieved a minimal disease state, and two-fifths achieved
either a significant clinical short-term response or inactive
disease by one year. Treatment responses appeared simi-
lar between the two biologic therapies, although low num-
bers prevented robust comparisons. Our observations of
anakinra being used first-line in some patients, despite the
availability of tocilizumab, may reflect clinicians’ prefer-
ences based on clinical scenarios and this needs further
exploration. This is important to address and may inform
future treatment guidelines for systemic JIA.
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